Table 3.
Delivered (186Re-HEDP) and extrapolated median, minimum and maximum absorbed doses for the patient population and absorbed doses that cover 50% of the total disease volume of the population (D50)
| Radiopharmaceutical | Median [min–max] absorbed dose (Gy) | Diff. from 186Re-HEDP (%) | D50 (Gy) |
| 32P-Na3PO4 | 10.4 [2.3–55.4] | –41 | 11.5 |
| 89Sr-dichloride | 21.8 [4.5–117.6] | 25 | 23.1 |
| 153Sm-EDTMP | 12.2 [3.3–57.7] | –32 | 13.0 |
| 166Ho-DOTMP | 2.7 [0.6–11.8] | –85 | 3.7 |
| 177Lu-EDTMP | 14.0 [3.7–72.0] | –20 | 14.8 |
| 186Re-HEDP | 17.7 [3.9–87.5] | – | 18.4 |
| 188Re-HEDP | 6.3 [1.5–27.1] | –64 | 7.6 |